Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

Merck pulled off its $10 billion buyout of Verona Pharma last month with little of the wheeling and dealing that typically ...

The stock's rise snapped a four-day losing streak.

Janux Therapeutics Inc. (NASDAQ:JANX) is one of the best small cap stocks with biggest upside potential. On August 5, Janux Therapeutics announced a clinical milestone in its collaboration with Merck ...

Merck & Co., Inc. (NYSE:MRK) is included in our list of the 10 Most Undervalued Value Stocks to Buy Now. On August 12, 2025, ...

Merck trades at a low P/E with strong financials, Keytruda growth, and a solid 3.9% yield, while its pipeline offsets future risks. Read why MRK stock is a buy.

Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in ...

Merck & Co.’s said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal of overall survival (OS) as a treatment for a type of ...

Merck & Co. has bailed early on a phase 3 test of the anti-TIGIT antibody vibostolimab after a high rate of discontinuations rendered the trial's success unlikely. The Big Pharma had been ...

Merck acquired sotatercept via its $11 billion acquisition of Acceleron Pharma Inc in 2021, underscoring the company’s commitment to advancing innovative therapies for serious medical conditions.

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed.

Shares of Merck & Co. Inc. slumped Tuesday, after the drug giant reported a rare revenue miss amid disappointing sales of two of its three biggest drugs and announced a $3 billion cost-cutting ...